Gilead Sciences, Inc. $GILD Stock Sold by Investment House LLC

Investment House LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 74.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,232 shares of the biopharmaceutical company’s stock after selling 12,165 shares during the period. Investment House LLC’s holdings in Gilead Sciences were worth $631,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in GILD. Bank of Nova Scotia purchased a new stake in Gilead Sciences during the second quarter valued at $100,056,000. OMERS ADMINISTRATION Corp bought a new position in Gilead Sciences during the second quarter valued at $55,754,000. Groupe la Francaise grew its stake in shares of Gilead Sciences by 30.9% in the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock worth $6,270,000 after buying an additional 11,712 shares in the last quarter. Baird Financial Group Inc. grew its stake in shares of Gilead Sciences by 3.6% in the 2nd quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after buying an additional 10,206 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in shares of Gilead Sciences in the 2nd quarter worth $6,251,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on GILD shares. Bank of America boosted their target price on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a report on Tuesday. Morgan Stanley lowered their price target on shares of Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating for the company in a report on Wednesday, October 7th. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Truist Financial lifted their price target on Gilead Sciences from $150.00 to $158.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $185.00 price objective on shares of Gilead Sciences in a research note on Friday. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $159.81.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the sale, the insider owned 118,234 shares in the company, valued at $16,273,727.76. This trade represents a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of Gilead Sciences stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total value of $2,229,600.00. Following the sale, the chief executive officer owned 577,133 shares of the company’s stock, valued at approximately $85,785,049.12. This trade represents a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 111,000 shares of company stock worth $15,877,860 over the last quarter. 0.30% of the stock is owned by insiders.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Inflammation pipeline expanded: Gilead agreed to acquire PepStar Therapeutics’ investigational oral IL-23R inhibitor program, including HCXT-2001, for approximately $1.275 billion in cash. The drug is intended for inflammatory bowel disease and could be developed alone or alongside Gilead’s emvistegrast, strengthening the company’s longer-term growth prospects. Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001
• Positive Sentiment: HIV development update: An ongoing study of a potential weekly oral HIV treatment adds another option to Gilead’s long-acting HIV portfolio. Positive clinical progress could support the company’s dominant HIV franchise and future revenue durability. Gilead’s Weekly HIV Pill Study Adds Long-Acting Firepower
• Positive Sentiment: Oncology collaboration: BioNTech and Gilead will test Gilead’s sacituzumab govitecan with BioNTech’s pumitamig in a global Phase 3 trial for advanced triple-negative breast cancer. The collaboration may improve the commercial potential of Gilead’s oncology platform, although clinical success remains uncertain. BioNTech, Gilead to Test Drug Combination
• Positive Sentiment: Favorable analyst and earnings expectations: TD Cowen reiterated a Buy view, while analysts indicated that Gilead could beat expectations in its upcoming quarterly report. Such forecasts support sentiment, though they are not guarantees of results. Gilead Sciences Receives a Buy from TD Cowen
• Neutral Sentiment: Gilead plans to present new data on rare liver diseases at The Liver Meeting 2026. The presentations could generate future catalysts, but no immediate clinical results were reported. Gilead to Present New Liver-Disease Data
• Negative Sentiment: Legal overhang: Gilead will pay $45 million to settle Texas Medicaid claims alleging unlawful incentives to encourage providers to prescribe its medicines. The financial cost is modest relative to Gilead’s size, but the settlement adds regulatory and reputational risk. Gilead Sciences to Pay $45 Million in Texas Medicaid Settlement

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $156.04 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences, Inc. has a 1 year low of $114.02 and a 1 year high of $160.51. The firm has a 50-day simple moving average of $149.10 and a two-hundred day simple moving average of $137.85.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.01 earnings per share. As a group, research analysts anticipate that Gilead Sciences, Inc. will post -0.47 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a dividend of $0.82 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. Gilead Sciences’s payout ratio is presently -122.85%.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.